acf/google-ad-placement

<ul>
	<li>Aldeyra Therapeutics Inc&nbsp;ALDX&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/04/b20822874/aldeyra-therapeutics-inc-announces-proposed-125-million-public-offering-of-common-stock" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">intends to sell $125 million</a>&nbsp;shares of its common stock in an underwritten public offering.&nbsp;</li>
	<li>Underwriters will have an option to purchase up to an additional $18.75 million of shares.</li>
	<li>Aldeyra intends to use the net proceeds to prepare a potential marketing application submission of its lead compound, reproxalap, the preparations for its commercial launch, if approved, pipeline development programs, and working capital purposes.</li>
	<li>Jefferies and SVB Leerink are acting as joint book-running managers for the offering.</li>
	<li>Yesterday, the company&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/04/20809263/aldeyra-therapeutics-stock-is-trading-higher-on-acing-allergic-conjunctivitis-study-with-reproxal" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">announced positive top-line results</a>&nbsp;from the Phase 3 trial evaluating 0.25% reproxalap in allergic conjunctivitis, sending shares to climb more than 30%.</li>
	<li>Data showed that Reproxalap easily achieved the primary endpoint of the study (reduction in eye itching) and secondary endpoints with a high level of statistical significance.</li>
	<li>Aldeyra&#39;s next step is to meet with the FDA about a path to approval for reproxalap. This meeting is expected to take place in the second half of this year, with a potential regulatory filing for approval on the way afterward.</li>
	<li>The company had cash and equivalents of $138.4 million as of March 31, 2021.</li>
	<li>Price Action:&nbsp;ALDX shares are down 5.4% at $14.05 in the premarket on the last check Wednesday.</li>
</ul>

Biotech

News

Health Care

Offerings

Small Cap

General

Aldeyra Seeks To Raise $125M Via Equity To Support Reproxalap US Application - Aldeyra Therapeutics (NASDAQ:ALDX)

Vandana Singh

Aldeyra Therapeutics

Briefs

ALDX

Aldeyra Seeks To Raise $125M Via Equity To Support Reproxalap US Application

Aldeyra Therapeutics Inc

Application error: a client-side exception has occurred (see the browser console for more information).